Insmed (NASDAQ:INSM) Sees Large Volume Increase - Here's What Happened

Insmed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insmed shares surged amid takeover speculation, with Sanofi reportedly weighing an acquisition; no formal proposal has been made. Trading volume reached 3.4 million shares, 14% above its daily average, and trading was briefly halted for volatility.
  • Analysts maintain a “Moderate Buy” consensus with an average price target of $196.52, though recent ratings included both upgrades and downgrades.
  • Latest quarterly revenue rose 268.4% year over year to $524.4 million, topping estimates, while the company’s loss per share of $0.46 was wider than the $0.38 loss analysts expected.
  • Five stocks to consider instead of Insmed.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) saw unusually-strong trading volume on Thursday. 3,398,887 shares traded hands during trading, an increase of 14% from the average daily volume of 2,982,692 shares. The stock last traded at $136.6630 and had previously closed at $119.80.

Insmed News Summary

These are some of the INSM news items that stood out recently:

  • Positive Sentiment: Takeover speculation lifted the stock, as a potential acquisition could offer shareholders a premium. Any transaction remains uncertain unless Sanofi makes a formal proposal. Insmed Soars 18% on Report That Sanofi Is Weighing a Takeover
  • Positive Sentiment: Call-option purchases were reported well above their average daily volume, consistent with heightened bullish speculation around the takeover reports.
  • Neutral Sentiment: Trading in INSM was briefly paused under a Limit Up-Limit Down (LULD) volatility mechanism, reflecting sharp price movement rather than a change in the company’s fundamentals.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on INSM shares. The Goldman Sachs Group initiated coverage on Insmed in a research report on Thursday, September 24th. They set a "buy" rating and a $188.00 target price on the stock. Wolfe Research cut Insmed from an "outperform" rating to a "peer perform" rating in a research note on Monday, October 12th. Guggenheim cut their target price on Insmed from $205.00 to $201.00 and set a "buy" rating on the stock in a report on Monday, November 2nd. Roth Capital restated a "buy" rating and set a $198.00 target price (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. Finally, Evercore reissued an "outperform" rating and set a $170.00 price objective on shares of Insmed in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $196.52.

View Our Latest Stock Analysis on INSM

Insmed Stock Up 19.0%

The firm has a market cap of $31.27 billion, a price-to-earnings ratio of -50.48 and a beta of 0.83. The business's 50-day moving average is $110.51 and its 200-day moving average is $122.84. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. Insmed's quarterly revenue was up 268.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.75) earnings per share. On average, equities analysts predict that Insmed, Inc. will post -1.86 EPS for the current year.

Insider Buying and Selling

In related news, Director David Brennan sold 25,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company's stock, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the business. Pictet Asset Management Holding SA grew its holdings in Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company's stock worth $200,845,000 after acquiring an additional 537,188 shares during the last quarter. Bellevue Group AG lifted its position in shares of Insmed by 8.2% during the third quarter. Bellevue Group AG now owns 1,508,034 shares of the biopharmaceutical company's stock worth $172,127,000 after purchasing an additional 114,616 shares in the last quarter. Sei Investments Co. lifted its position in shares of Insmed by 56.8% during the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock worth $228,239,000 after purchasing an additional 505,624 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Insmed during the second quarter valued at approximately $139,966,000. Finally, Assenagon Asset Management S.A. grew its stake in shares of Insmed by 480.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company's stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insmed Right Now?

Before you consider Insmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.

While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines